» Articles » PMID: 1721625

Glioblastoma Expression of Vitronectin and the Alpha V Beta 3 Integrin. Adhesion Mechanism for Transformed Glial Cells

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1991 Dec 1
PMID 1721625
Citations 125
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma multiforme, the most malignant astroglial-derived tumor, grows as an adherent mass and locally invades normal brain. An examination of adult cerebral glioblastoma biopsy material for the expression of adhesive proteins that might potentiate adhesion and invasion demonstrated tumor cell-associated vitronectin (5/5). In contrast, vitronectin was not detected associated with glial cells in low grade astroglial tumors (0/4), reactive astrogliosis (0/4), or in normal adult cortex and cerebral white matter (0/5). Also, a wide variety of other adhesive ligands were absent from the glioblastoma tumor parenchyma. The alpha v beta 3 integrin was the only vitronectin receptor identified in glioblastoma tumors in situ, and was also not expressed on low grade astroglial-derived tumors, reactive astrogliosis, or on glia or neurons in normal adult cortex and cerebral white matter. In a cell attachment assay, cultured glioblastoma cells attached to the parenchyma of glioblastoma tumor cryostat sections at the sites of vitronectin expression, but failed to attach to normal brain. This adhesion was inhibited by antibodies directed against vitronectin, the alpha v beta 3 integrin, and with an Arg-Gly-Asp-containing peptide. These data provide evidence for a cell adhesion mechanism in glioblastoma tumors that might potentiate glioblastoma cell invasion of normal brain.

Citing Articles

Irisin and Metastatic Melanoma: Selective Anti-Invasiveness Activity in BRAF Wild-Type Cells.

Serrati S, Zerlotin R, Manganelli M, Di Fonte R, Dicarlo M, Oranger A Int J Mol Sci. 2025; 26(2).

PMID: 39859367 PMC: 11765811. DOI: 10.3390/ijms26020652.


Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?.

Lopez-Carrasco A, Vieco-Marti I, Granados-Aparici S, Acevedo-Leon D, Estan-Capell N, Portugal R Int J Mol Sci. 2024; 25(16).

PMID: 39201421 PMC: 11354570. DOI: 10.3390/ijms25168733.


The Role of αvβ3 Integrin in Cancer Therapy Resistance.

Pachane B, Selistre-de-Araujo H Biomedicines. 2024; 12(6).

PMID: 38927370 PMC: 11200931. DOI: 10.3390/biomedicines12061163.


Optimizing the enzymatic release of MMAE from DGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker.

Zambra M, Randelovic I, Talarico F, Borbely A, Svajda L, Tovari J Front Pharmacol. 2023; 14:1215694.

PMID: 37492088 PMC: 10363981. DOI: 10.3389/fphar.2023.1215694.


Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.

Chang M, Gao F, Pontigon D, Gnawali G, Xu H, Wang W J Am Chem Soc. 2023; 145(25):14155-14163.

PMID: 37327395 PMC: 11249063. DOI: 10.1021/jacs.3c05159.


References
1.
Neugebauer K, Emmett C, Venstrom K, Reichardt L . Vitronectin and thrombospondin promote retinal neurite outgrowth: developmental regulation and role of integrins. Neuron. 1991; 6(3):345-58. DOI: 10.1016/0896-6273(91)90244-t. View

2.
Jones T, Ruoslahti E, Schold S, Bigner D . Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res. 1982; 42(1):168-77. View

3.
Ruoslahti E . Integrins. J Clin Invest. 1991; 87(1):1-5. PMC: 294975. DOI: 10.1172/JCI114957. View

4.
Albelda S, Mette S, Elder D, Stewart R, Damjanovich L, Herlyn M . Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990; 50(20):6757-64. View

5.
Niculescu F, Rus H, Porutiu D, Ghiurca V, Vlaicu R . Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis. 1989; 78(2-3):197-203. DOI: 10.1016/0021-9150(89)90223-2. View